2023 Fiscal Year Final Research Report
Pediatric universal screening in Kagawa
| Project/Area Number |
20K08474
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松永 圭司 香川大学, 医学部附属病院, 助教 (70791052)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 家族性高コレステロール血症 |
|---|
| Outline of Final Research Achievements |
Pediatric familial hypercholesterolemia (FH) screening, initiated through the School Children's Lifestyle-Related Disease Prevention Examination (Kagawa Pediatric Examination), has demonstrated significant benefits for both FH patients and their families. To date, over 400 FH parent-child pairs have been diagnosed in Kagawa Prefecture, leading to an FH diagnosis rate exceeding 10%. Moreover, the scientific evidence gathered in Kagawa has substantially influenced the diagnostic criteria established in the "Pediatric FH Treatment Guidelines 2022." Furthermore, the incremental cost-effectiveness ratio (ICER) associated with pediatric FH screening is approximately 150,000 yen/QALY, far below the 500,000 yen/QALY threshold for new drug introduction, highlighting the economic advantages of pediatric FH screening.
|
| Free Research Field |
循環器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
小児生活習慣病予防健診を起点とした小児ＦＨスクリーニングにより、FH親子400名以上を診断され、香川県でのFH診断率は10%を超えています。また、香川で得られた科学的エビデンスは、「小児FH診療ガイドライン2022」の診断基準にも大きく反映されました。さらに、小児FHスクリーニング実施にともなう増分費用効果比は約15万円／１QALYであり、小児FHスクリーニングは医療経済的にも優れていることを示しました。香川県における小児FHスクリーニング研究は、FH患児とその家族の早期診断・早期治療を実現し、健康寿命の延伸に貢献する可能性を示しました。
|
